Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer

The care of metastatic colorectal cancers is based on combination chemotherapies including 5-fluorouracil, oxaliplatin, irinotecan, and monoclonal antibodies targeting the epidermal growth factor receptor or vascular endothelial growth factor. The regimen is determined based on the patient’s molecul...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hélène Bellio, Aurélie Bertaut, Alice Hervieu, Sylvie Zanetta, Audrey Hennequin, Julie Vincent, Rémi Palmier, Leila Bengrine-Lefevre, François Ghiringhelli, Jean-David Fumet
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
5-fluorouracil
irinotecan
oxaliplatin
bevacizumab
chemotherapy metastatic colorectal cancer
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/8925284c64c64aa89355bb16026e4137
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/8925284c64c64aa89355bb16026e4137

Documents similaires